Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
May 23, 2026, 08:15Alexander Krupp: Asundexian Receives Priority Review Designation from China‘s NMPA
-
May 23, 2026, 07:59Toward a Dedicated Framework for MIg-Driven Hemostatic Disorders – JTH
-
May 23, 2026, 07:53Ankit Panthari: Can Haemophilia Serve as A Health System Model for Other Rare Diseases in India?
-
May 23, 2026, 07:43Ted Roh: Indonesia’s Plasma Fractionation Plant Wins Social Infrastructure Deal of the Year at the IJGlobal Awards 2025
-
May 23, 2026, 07:36Angie Read: Stories of Strength and Resilience on The Latest Episode of Stroke Sisters
-
May 23, 2026, 07:30Ozlem Fidanci: Reflections From WHA79 on the Future of Stroke Care
-
May 23, 2026, 07:21Ney Carter Borges: Where the Benefit Appears in Dual Antiplatelet Therapy
-
May 23, 2026, 05:38SIUH Advances Precision Stroke Care with Vena MicroAngioscope – Northwell Health
-
May 23, 2026, 05:31Kalyan Roy: Precision Blood Matching in Transfusion-Dependent Thalassaemia